Welcoming Caroline Solon, Senior Director Global Market Access, within our policy, access, value, and evidence capability

We are pleased to welcome Caroline Solon to her new role, Senior Director Global Market Access, with PRMA Consulting, part of Fishawack Health. In this update, Caroline shares her thoughts on the increasing importance of policy, access, value, and evidence, and explains how she will be helping clients to create the connections that make better health happen.

Driving commercial and access strategies for global markets with a team of committed collaborative experts 

I have a wealth of experience that I look forward to using to help our clients navigate complex policy, access, value, and evidence systems. From market analysis and strategy to HEOR evidence synthesis, through to pricing, contracting, and distribution, I have built and driven commercial and access strategies for the US and global markets. 

It was important to me that I brought this experience to an organization of bright, motivated people who work hard, are collaborative, are effective communicators, and have a healthy respect for each other’s personal and professional lives. 

Who you work with plays such a big role in your overall experience at work, your mental health, and your general day-to-day life. Everyone I have met at PRMA Consulting and Fishawack Health has a strong passion and focus for the work they do. They are a community of experts who think big as well as deep, yet they are also committed to cultivating a healthy work-life balance for themselves and their teams. 

Uncovering the human relevance in science and data to create patient-centric approaches to access 

An example of a project I am proud of working on is from the COVID-19 pandemic. 

I had the opportunity to co-create a patient-centric toolkit to support self-management of mild to moderate COVID-19 symptoms, which prioritized health equity in its development. Social determinants of health and health literacy were key factors in shaping the design of the toolkit to ensure it was accessible and usable by individuals across the socioeconomic continuum. 

At the time, most resources either focused on severe disease or did not offer actionable solutions for patients. I was very proud to be involved in an initiative that was addressing a very real unmet need at a time of great uncertainty in the world. 

 

The increasing importance of policy, access value, and evidence 

Evolving health policy, increasingly saturated competitive landscapes, budgetary constraints, and the growing complexities of population (and individual) health means the importance of successful and timely commercialization of new therapies and diagnostics is at an all-time high. 

For biopharma manufacturers operating in the current healthcare environment, the pace of change is accelerating; juggling market access strategies and pull-through across markets, products, and therapeutic areas is becoming increasingly complex. 

That’s where our policy, access, value, and evidence team add value: our experts offer thought partnership, address gaps in knowledge, and provide insights into the current access barriers and opportunities across markets. This enables us to help our clients design and execute successful market access strategies to enhance patient access to healthcare. 

Creating the connections that make better health happen 

Ultimately, our primary goal is to help optimize health for patients and wider society; so, it’s our responsibility to ensure we are making and prioritizing meaningful connections that continually move us forward and make better health happen. 

In my daily work, this is about leveraging our integrated way of working, bringing experts, ideas, strategies, insights, and data together. 

This might be internally within our Group – for example, sharing the latest knowledge and experiences across teams to enhance our service offerings and elevating the quality of work we deliver to clients. Or it can be externally – for example, as strategic thought partners to our clients, synthesizing current insights and robust data to provide a clear picture of a challenge or opportunity and providing innovative solutions to optimize their access strategies. 


Valuing difference – fostering a culture that is equitable, diverse, and inclusive
 

Company values form the foundation of both the employee and client experience, and our company value of “valuing difference” is especially meaningful for me. 

Diversity, whether it be in experience, culture, knowledge, or thought process, is key to generating well-rounded perspectives. In my personal experience, environments like ours – where diversity is celebrated, valued, and actively encouraged – offer far richer opportunities for successful collaboration and both personal and professional growth. 

The team here really embodies this company value and I’m excited for the opportunity to collaborate with such a diverse, dynamic, and inquisitive global team. 

We are always looking for people who will deliver first-class work 

If you’d like to find out more about career opportunities within our organization, please look through our current vacancies or get in touch with your CV. 

FREE Ebook

Digital therapeutics: policy, access, value, and evidence

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...

Webinars

Driving BioPharma Access in Europe: Insights ...

Read more >

EBOOK

Value, Evidence, and Access: insights for ...

Read more >

EBOOK

Digital therapeutics: policy, access, value, and ...

Read more >

Blog

Evidence generation and launch strategies in ...

Read more >

Articles

Value, Evidence, and Access: insights for ...

Read more >

Blog

Digital therapeutics: value, evidence, and access ...

Read more >

EBOOK

Precision medicine: positioning for market access ...

Read more >

Blog

Welcoming Philip Drew, Head of Global ...

Read more >

Blog

Evidence supporting reimbursement of digital therapeutics

Read more >

Blog

Reducing the care gap in cancer ...

Read more >

Blog

ISPOR 2023: insight from Avalere’s expert ...

Read more >

Webinars

Positioning for market access success in ...

Read more >

Blog

AMCP 2023: key trends and highlights

Read more >

Blog

Why a market access career in ...

Read more >

Blog

E-learning for market access professionals

Read more >

Blog

Showcasing Robust Policy, Access, Value, and ...

Read more >

Blog

Principles of HTA Early Scientific Advice ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Articles

Market access success in the evolving ...

Read more >

Blog

5 benefits of e-learning for your market ...

Read more >

Articles

Cell and gene therapy: navigating the ...

Read more >

Blog

Market access careers in the Asia-Pacific ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Blog

The benefits of utilizing Early Scientific ...

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >

Blog

Cell and gene therapies: common challenges ...

Read more >

Blog

Avalere’s Healthcare Industry Outlook Report 2023

Read more >

Blog

Driving BioPharma value, evidence, and access ...

Read more >